Navigation Links
Macrocyclics presenta nuevos productos
Date:1/10/2014

DALLAS, 10 de enero de 2014 /PRNewswire/ -- Macrocyclics, Inc. (compañía de AREVA Med) anunció hoy la presentación de cuatro nuevos productos que ampliarán las aplicaciones de imágenes PET con cobre-64 y galio-68 usando plataformas quelatantes basadas en NOTA. Además, un nuevo conjugado de DOTA basado en serotonina ofrece el potencial para obtener imágenes de neurotransmisión serotoninérgicas utilizando un radioisótopo o con gadolinio mediante imágenes por resonancia magnética (MRI).

(Logo: http://photos.prnewswire.com/prnh/20130523/DA20136LOGO)

Visite www.macrocyclics.com para obtener más información.

MÁS ACERCA DE MACROCYCLICS
Macrocyclics es el líder global en tecnologías de agentes quelatantes de alto desempeño para la medicina desde 1995. El equipo de Macrocyclics se dedica a proveer a los clientes agentes quelatantes y servicios tanto establecidos como innovadores para superar los desafíos de las imágenes moleculares y la medicina nuclear. www.macrocyclics.com

MÁS ACERCA DE AREVA MED
AREVA Med es una subsidiaria de AREVA que se especializa en el desarrollo de tratamientos innovadores para luchar contra el cáncer. AREVA Med creó nuevos procesos para producir plomo-212 (²¹²Pb) de alta pureza, un metal poco común que actualmente se encuentra en el centro de prometedoras investigaciones de medicina nuclear. En 2011, AREVA Med adquirió Macrocyclics, líder global en tecnología de agentes quelatantes de alto desempeño. AREVA Med también formó alianzas con socios científicos de primer nivel, como el Instituto Nacional del Cáncer (National Cancer Institute, NCI), la Universidad de Alabama en Birmingham (University of Alabama at Birmingham, UAB) y el Instituto Nacional Francés de Salud e Investigación Médica (French National Institute of Health and Medical Research, Inserm). En 2012, AREVA Med y Roche formaron una alianza estratégica para crear nuevos tratamientos avanzados de radioinmunoterapia alfa para atacar y matar ciertos tipos de células cancerígenas muy agresivas. Para obtener más información: http://arevamed.areva.com/ o www.targetedtrials.com.

Macrocyclics
Garry Kiefer
Teléfono: +1 972 250 2248
Fax: +1 972 250 2245
info@macrocyclics.com

AREVA Med
Alison Tise
Teléfono: +1 301 841 1673
Fax: +1 434 382 4250
alison.tise@areva.com

FUENTE  Macrocyclics, Inc.

FUENTE Macrocyclics, Inc.


'/>"/>
SOURCE Macrocyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Macrocyclics apresenta novos produtos
2. Macrocyclics introduces new products
3. Healthcare Companies Report Conference Presentation Schedule, Stock Price Updates, and Clinical Study Results - Research Report on Medivation, Envision Healthcare, Fonar, Idera Pharma, and Neurocrine
4. Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan
5. Cepheid to Webcast Upcoming Financial Presentation
6. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
7. Pharmacyclics Announces Data Presentations for Ibrutinib in B-Cell Malignancies
8. Cell Therapeutics Announces Presentation of Interim Results from Phase 2 Tosedostat Trial in Older Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) at ASH Annual Meeting
9. Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
10. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
11. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... -- Bayer has awarded grants totaling more than $2 million to ... Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers ... and Uniformed Services University of the Health Sciences in ... were announced last night during a reception at the International ... Berlin, Germany . ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology:
(Date:7/28/2017)... ... July 28, 2017 , ... Shamanic Teacher ... and Spiritual Awakening, is proud to announce the return of her increasingly ... interested in learning more about the mystical world of shamanism, nature wisdom, the ...
(Date:7/27/2017)... ... July 27, 2017 , ... Standard Process is ushering in a new ... the North Carolina Research Campus (NCRC) in Kannapolis, North Carolina and by announcing a ... the fall of this year, occupying over 10,000 square feet on the first floor ...
(Date:7/27/2017)... ... July 27, 2017 , ... Somnoware, a leading ... (PSG) distributed scoring solution to its healthcare management platform. This solution provides physicians ... speed and functionality of scoring in the cloud is on par with doing ...
(Date:7/27/2017)... ... ... eating isn’t always easy. Currently, more than 80 percent of Americans fail to eat the ... and sugar. This trend may help explain why the obesity rate seems stuck. The most ... a culture, we seem to have food on the brain more. "We eat two more ...
(Date:7/27/2017)... NY (PRWEB) , ... July 27, 2017 , ... ... President Barack Obama from 2012-2016, will keynote Day 2 of the HIMSS Healthcare ... event kicks off at the Sheraton Boston Hotel, Sept. 11-13, 2017. , Daniel ...
Breaking Medicine News(10 mins):